Millennium Management LLC Raises Stock Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Millennium Management LLC lifted its stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) by 151.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 84,829 shares of the company’s stock after buying an additional 51,139 shares during the quarter. Millennium Management LLC’s holdings in DiaMedica Therapeutics were worth $461,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Dimensional Fund Advisors LP increased its position in shares of DiaMedica Therapeutics by 14.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company’s stock worth $105,000 after acquiring an additional 2,380 shares during the period. LPL Financial LLC increased its holdings in DiaMedica Therapeutics by 8.2% during the fourth quarter. LPL Financial LLC now owns 152,000 shares of the company’s stock valued at $825,000 after buying an additional 11,500 shares during the period. Balyasny Asset Management L.P. purchased a new position in DiaMedica Therapeutics during the fourth quarter valued at approximately $79,000. Y Intercept Hong Kong Ltd purchased a new position in DiaMedica Therapeutics during the fourth quarter valued at approximately $81,000. Finally, Raymond James Financial Inc. purchased a new position in DiaMedica Therapeutics during the fourth quarter valued at approximately $83,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of DiaMedica Therapeutics in a report on Thursday, May 29th.

DiaMedica Therapeutics Stock Down 1.4%

Shares of DMAC stock opened at $4.08 on Tuesday. The firm has a market cap of $174.96 million, a price-to-earnings ratio of -7.29 and a beta of 1.23. The company’s 50 day moving average is $3.92 and its 200 day moving average is $4.99. DiaMedica Therapeutics Inc. has a 52-week low of $2.14 and a 52-week high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). During the same quarter in the previous year, the business earned ($0.14) EPS. Analysts anticipate that DiaMedica Therapeutics Inc. will post -0.59 EPS for the current fiscal year.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.